Innovation Adoption Barriers

5 invisible forces that block innovation (and hide in even the best teams). By the time you realize innovation is stuck, it’s probably already been stalled for 12 months. Leaders often assume innovation gets blocked by lack of ideas or talent. In reality, it’s much more subtle. 5 quiet blockers of innovation: 1. Success Becomes a Straitjacket When what’s always worked keeps working, there's no urgency to try something new.  The team becomes optimized for consistency, not creativity. 2. The Pressure to Perform Kills Risk High expectations create a culture where failure is taboo.  Innovation needs room to fail.  Without psychological safety, bold ideas stay buried. 3. Over-Optimization Leaves No Slack Every hour is scheduled, every resource allocated.  But innovation lives in the white space.  No slack = no spark. 4. Groupthink in Disguise Alignment is good, until it morphs into uniform thinking. Breakthroughs require dissent, debate, and diverse perspectives. 5. Too Much Focus on the Now Top performers solve today’s problems. But innovation demands time for what’s next. When urgent always beats important, the future gets shortchanged. Don’t assume innovation will just “happen.” → Make space for exploration → Reward smart risks → Invite diverse thinking → Tolerate failure along the way Innovation doesn’t compete with performance.  It fuels the next level of it. → Which of these 5 roadblocks have you seen most often? -- Hi, I’m an executive coach helping leaders get results, lead strategically, and excel in their careers. 🔹 Follow me (LK Pryzant) for more.

Only a small fraction of healthcare providers use AI tools for clinical decisions. A new systematic review of 92 studies explains why. The barriers aren't just "clinicians don't trust AI." They're structural, organizational, and technological… and they interact in ways that make adoption harder than most vendors acknowledge. Researchers grouped barriers using the Human-Organization-Technology framework. Human barriers: Lack of training, increased workload, mistrust, over-reliance that may deskill providers, concerns about weakening patient relationships. Organizational barriers: Limited infrastructure, weak leadership engagement, poor change management, unclear accountability, absent regulations. Technology barriers: Data privacy, algorithmic bias, insufficient accuracy, poor transparency, limited workflow adaptability. Data privacy and quality concerns appeared in over 30 studies each… the most frequently cited issues. What surprised me: Less than 20% of studies focused on specific AI tools in clinical settings. Most research examines general perceptions of AI rather than real-world application experiences. We're studying what clinicians think about AI in theory more than what actually happens when they use it in practice. The authors propose a system-level framework: assessment, implementation, and continuous monitoring. Links barriers to actionable strategies aligned with patient safety. The core insight: AI adoption isn't about better algorithms. It's about aligning people, processes, and technologies. Most AI companies optimize for algorithmic performance. But adoption barriers are rarely "the model isn't accurate enough." They're "we don't have integration infrastructure," "leadership hasn't prioritized this," "clinicians can't verify outputs," "we can't ensure data privacy," "the workflow doesn't accommodate this." Solving algorithmic accuracy doesn't address those constraints. *** Is your organization addressing AI adoption barriers at the system level, or just buying better tools and expecting behavior change? — Source: Safety Science - "Artificial intelligence adoption challenges from healthcare providers' perspectives" (DOI: 10.1016/j.ssci.2025.107028)

I’ve found that most HealthTech founders assume innovation is their differentiator. In practice, it rarely is. The UK doesn’t lack technical brilliance or world-class research. What it lacks is translation – the ability to move from promising R&D to meaningful, sustained adoption inside the NHS. The hardest problems aren’t technical. They’re organisational. Structural, financial, and cultural frictions shape the pace of progress far more than the quality of the technology itself. Procurement is the clearest example. Despite endless reform attempts, it still prizes unit cost over value. I’ve watched technologies capable of saving millions across a pathway fail an affordability test because their upfront cost exceeded a local trust’s limit. It’s no surprise that nearly a third of suppliers now avoid NHS tenders altogether – the commercial terms just don’t work. Funding models make it worse. More than 70% of NHS trust leaders cite financial constraints as the main barrier to digital transformation. Even when solutions clearly deliver long-term savings, capital accounting rules often prevent reinvestment of those gains into operational budgets. The result is predictable: effective innovations that never reach scale because the fiscal space to adopt them simply doesn’t exist. Then there’s the human system. Clinical adoption depends less on technical brilliance and more on how technology fits the rhythm of care. Too often it adds friction – extra logins, duplicate steps, more admin. Around one in three trust leaders still call poor IT infrastructure a critical barrier. And culture matters just as much. Clinicians’ scepticism toward opaque AI tools isn’t resistance. It’s accountability. Trust has to be earned through transparency, evidence, and co-development. The technologies that scale are the ones that integrate clinicians early, turning potential critics into advocates. Yes, there are positive shifts. NICE’s move to consider cost-effectiveness, not just cost-saving, is significant. Regulatory agility has improved. But the underlying system frictions remain. The UK is still a world-class testbed, not yet a world-class market. After two decades, my conclusion is simple: HealthTech success in the UK isn’t about innovation quality anymore. It’s about system mastery. The winners will be those who can navigate NHS economics, align incentives, build trust, and embed change deep within clinical practice. The frontier, as I see it now, isn’t technical. It’s organisational. P.S. If you’re a HealthTech founder, DM to explore how to navigate the system, not just build for it.

AI Adoption: Reality Bites After speaking with customers across various industries yesterday, one thing became crystal clear: there's a significant gap between AI hype and implementation reality. While pundits on X buzz about autonomous agents and sweeping automation, business leaders I spoke with are struggling with fundamentals: getting legal approval, navigating procurement processes, and addressing privacy, security, and governance concerns. What's more revealing is the counterintuitive truth emerging: organizations with the most robust digital transformation experience are often facing greater AI adoption friction. Their established governance structures—originally designed to protect—now create labyrinthine approval processes that nimbler competitors can sidestep. For product leaders, the opportunity lies not in selling technical capability, but in designing for organizational adoption pathways. Consider: - Prioritize modular implementations that can pass through governance checkpoints incrementally rather than requiring all-or-nothing approvals - Create "governance-as-code" frameworks that embed compliance requirements directly into product architecture - Develop value metrics that measure time-to-implementation, not just end-state ROI - Lean into understanability and transparency as part of your value prop - Build solutions that address the career risk stakeholders face when championing AI initiatives For business leaders, it's critical to internalize that the most successful AI implementations will come not from the organizations with the most advanced technology, but those who reinvent adoption processes themselves. Those who recognize AI requires governance innovation—not just technical innovation—will unlock sustainable value while others remain trapped in endless proof-of-concept cycles. What unexpected adoption hurdles are you encountering in your organization? I'd love to hear perspectives beyond the usual technical challenges.

Last year at Microsoft, I spent months untangling Microsoft Copilot’s global rollout. AI’s biggest roadblocks? They weren’t technical at all. Imagine a meeting room in Kauala Lumpur. Someone says, “We’ve always done it this way.” Another whispers, “AI will replace our jobs.” A third leans in: “Our data is too sensitive for AI.” Familiar script, right? Truth is, the toughest challenges weren’t coding or infrastructure, they were deep-seated habits and fears. The breakthrough? It always came from the believers. In every successful Copilot launch, we found our internal champions early like GAURAV JOSHI, Sergey Oreshin, the ones eager to explore, not argue. We trained them, armed them with quick wins, and let their teams see real ROI instead of vague promises. Progress snowballed from those first pockets of success. Here’s a three-step playbook I swear by: 1️⃣ Start with the believers: Map out your internal AI curiosity. 2️⃣ Equip and coach them: Focus on real teams, not abstract rollouts. 3️⃣ Let their results speak: Showcase ROI, then scale, fear melts before evidence. Every company talks about technical innovation, but it’s culture that makes or breaks AI adoption. So, what’s the single biggest cultural barrier you’ve seen hold back real innovation? Share your story below and let’s gather ideas that move the needle. (This is why I collect lessons weekly in Executive AI Essentials—check my profile if you want the next playbook.) PS: Pic made in wonderful Malaysia, but Nano Banana ironed my shirt :)

Here’s a truth about healthcare innovation we don’t talk about enough: (Great ideas often fail—not because they lack potential, but because they face resistance.) We often hear things like: “Technology will revolutionize medicine.” “Innovation is the key to better patient outcomes.” “New tools make healthcare more efficient.” But here’s the reality: Innovation in healthcare isn’t just about having great ideas; it’s about overcoming the barriers to adoption. Here’s why promising innovations often struggle: → Risk Aversion: Healthcare professionals prioritize safety and stick to proven methods unless there's undeniable evidence. → Disrupted Workflows: New tools can feel like complications, threatening established routines and patient interactions. → Time Pressures: Clinicians, already stretched thin, often lack time to learn and adapt to new systems. → Organizational Culture: Traditional mindsets can stifle innovation, favoring profit-driven solutions over simpler, impactful ideas. The takeaway? For innovation to thrive, healthcare must address these barriers with change management, engagement, and clear demonstrations of value. What’s your take? How can we foster innovation in such a risk-averse industry? Let’s discuss below! 👇

Why is scaling innovation in the NHS so challenging? After attending several digital health workshops and events with startups, scaleups, and NHS stakeholders recently, one theme continues to dominate conversations: frustration with the slow pace and challenges of adopting and more specifically scaling innovations across the NHS. To clarify, innovations are being adopted—but the journey to scale a proven, evidence-based, and cost-effective solution across the NHS can be extremely challenging. Here are some thoughts (personal and from event discussions) of the core challenges contributing to this. 🔵 Fragmented NHS landscape & procurement pains – The NHS isn’t one single entity but a network of thousands of independently run organizations, each with their own management priorities and procurement hurdles. Even if an innovation is adopted in one NHS Trust, rolling it out elsewhere often means starting from scratch. 🔵 Lack of centralized scaling mechanisms – There is no robust mechanism for scaling evidence-backed, cost-effective innovations across the NHS. Proven solutions often remain localized due to a lack of system-wide support. 🔵 Outdated digital infrastructure – Interoperability issues and outdated systems create barriers to seamless integration with clinical workflows. 🔵 Financial constraints – Cash flow remains a pressing issue, with many NHS Trusts focused on maintaining current services. Limited capital leaves little room for trialing or scaling new innovations. 🔵 Regulatory complexity and ambiguity – The rigorous regulatory environment ensures safety and quality but often creates significant challenges for innovators. Navigating standards and regulatory requirements involves lengthy, ambiguous, and resource-intensive processes. 🔵 Workforce burnout – The NHS workforce is stretched thin. Burnout and staff shortages leave little room for frontline staff to engage with or champion new ways of working. 🔵 Cultural resistance – Change, particularly in established workflows, often faces resistance at multiple levels, stalling adoption of new approaches and technologies. 🔵 Risk tolerance – There’s a critical need to rethink risk tolerance. Ironically, maintaining the status quo can be riskier in some cases than implementing newer solutions. Balancing safety with innovation remains a complex but necessary conversation. 🔵 Noise & hype - Separating credible innovations from hype remains a challenge. Tools like DTAC (Digital Technology Assessment Criteria) are a step in the right direction, but they could benefit from a revamp. Unfortunately, bad actors in the space can also spoil the landscape for everyone. Would love to hear perspectives on this: what do you see as the biggest barriers to adopting and scaling new innovations in the NHS? More importantly, what changes do you think are needed to pave the way for the NHS to adopt and scale innovations effectively at pace? #nhs #innovation

One-and-done gene therapies for blood disorders like sickle cell disease are genuine marvels of science. But—as a ZS analysis of 350 launches across 12 therapy areas reveals—translating that innovation into impact at scale depends on everything surrounding the therapy.    Recent reporting from STAT highlights that uptake for some of these therapies has been hampered by the seemingly mundane obstacle of patient cell collection—an operational step required to personalize treatment.     It isn’t a manufacturing foresight issue. It’s just where real-world complexity tends to surface.    And this isn't confined to advanced therapies. ZS research has found that product attributes (i.e., the science) account for only 10%-20% of adoption outcomes. Field teams, support services and reputation explain the rest.    As an industry we’ve been conditioned to focus on convincing HCPs “why to prescribe,” even as “how to prescribe” and “how to treat” have become the real barriers to adoption.     As a result, we’ve been putting 80% of our resources into a driver (i.e., scientific messaging) that influences only 20% of adoption decisions.    This is why we help clients design end-to-end systems — from molecule discovery through commercial execution — that explicitly map and remove the real barriers to treatment. Bold science is the price of entry. But it’s execution that turns ideas into impact that actually matters to patients. 

Most med device companies and investors talk about the TAM (Total Addressable Market). The winners are thinking and talking about the SOM (Serviceable Obtainable Market). I sat down with Joe Mullings recently to talk through this concept. There is a pattern that keeps emerging as I discuss with MA leaders in the industry - Companies think about proving clinical superiority and the patient population (TAM thinking). They think earlier about securing reimbursement pathways and clinical utility (SAM thinking). But, not many have mapped out the real-world adoption barriers that would prevent the actual use of the device (SOM thinking). SOM thinking is measuring real world friction. What makes a physician change their workflow? Where does budget authority actually sit in the hospital? What training barriers compete with OR time? How do reimbursement codes interact with existing procedure economics? As we discuss in the video about lung cancer screening, evidence-based practice doesn't become standard of care automatically. The market access leaders who understand this are ruthless in their focus on barrier identification and removal. This is what implementation science is all about. When the goal is adoption, and not just approval, the SOM is what counts. #BuildingCompanies #BuildingCareers #MarketAccess #MedTech

Fighting the AI Digital Divide in Healthcare AI scribes have been adopted by 86% of system-affiliated hospitals and 37% of independent facilities. AI solutions are integrated in 81% of urban hospitals and 56% of rural hospitals. Earlier this week, Vega Health submitted detailed comments to HHS on accelerating clinical AI adoption. The statistics above reveal an urgent problem, but the barriers go deeper than rural versus urban—they're systemic challenges holding back the entire healthcare ecosystem. After a decade at the Duke Institute for Health Innovation, the pattern is clear: the most well-resourced health systems launch innovation hubs and build transformative AI solutions. They have the resources and expertise to experiment, implement, and scale. Everyone else? They're facing the same workforce shortages and margin pressures without innovation budgets or data science teams. Here's what's upsetting: The AI solutions proven at academic medical centers could work everywhere. They improve outcomes. They reduce costs. They help clinicians do more with less. But at every layer of the healthcare AI stack, barriers prevent scaling: The database layer: Each health system records data differently. Mapping lab values, medications, and vital signs across systems is time-intensive, expensive, and prone to failures. The connection layer: Data access has become a negotiation rather than standard interoperability. Restrictive practices make integrations expensive and complicated, forcing health systems and their chosen vendors to navigate unnecessary technical and financial hurdles to access data. The evaluation layer: Each AI vendor reports performance differently. Health systems manage multiple technologies with no unified view of what's working, what's drifting, what needs to be sunset. Without comprehensive monitoring across technical accuracy, clinical adoption, actual outcomes, and ROI, even sophisticated organizations struggle to separate successful investments from expensive failures. The solutions exist. Regulatory sandboxes can accelerate safe innovation under appropriate guardrails. Silent trials enable rapid evaluation on diverse patient populations without exposing patients to potential harm. Platform infrastructure normalizes data preparation, standardizes implementation, and enables objective monitoring. Federal programs like the Rural Health Transformation Program create opportunity. State initiatives can structure funding for shared infrastructure. The FDA and ONC are reconsidering overly restrictive frameworks. But health systems need the ability to actually implement solutions without artificial barriers imposed at the data layer. Health system leaders: what barriers are you hitting trying to scale AI beyond pilot programs? What would it take to make proven solutions accessible in your environment? Our full letter from Vega Health to HHS: https://lnkd.in/ePykegvz